← FDA DRUG APPROVALS

FDA ANDA · ANDA217468

DIAZEPAM

Sponsor: NAVINTA LLC

APPLICATION
ANDA217468
TYPE
ANDA
ORIGINAL APPROVAL
2025-11-14
LATEST ACTION
2025-11-14
ROUTE
RECTAL
DOSAGE FORM
GEL
MARKETING STATUS
Prescription

Products

DIAZEPAMPrescription
DIAZEPAM 10MG/2ML (5MG/ML) · GEL · RECTAL
DIAZEPAMPrescription
DIAZEPAM 20MG/4ML (5MG/ML) · GEL · RECTAL
DIAZEPAMPrescription
DIAZEPAM 2.5MG/0.5ML (5MG/ML) · GEL · RECTAL

Approval history

2025-11-14UNKNOWN · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →